Aurobindo Pharma Limited (AUROPHARMA.NS)

INR 1266.0

(1.48%)

Market Cap (In INR)

735.29 Billion

Revenue (In INR)

290.01 Billion

Net Income (In INR)

31.72 Billion

Avg. Volume

1.42 Million

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
958.5-1592.0
PE
-
EPS
-
Beta Value
0.593
ISIN
INE406A01037
CUSIP
Y04527142
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Makkapati Satakarni B.E., M.B.A., Ph.D.
Employee Count
-
Website
https://www.aurobindo.com
Ipo Date
1996-01-15
Details
Aurobindo Pharma Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients, generic pharmaceuticals, and related services in India. The company primarily offers oral solids, injectables, and over-the-counter drugs, as well as active pharmaceutical ingredients and finished dosage forms for cardiovascular, central nervous system, gastroenterology, anti-allergies, anti-diabetics, anti-retroviral, antibiotics, dermatology, respiratory, and oncology. It is also involved in the development of a product pipeline in biosimilar and vaccine segments; and custom research and manufacturing activities for the bio-tech and pharmaceutical community. In addition, the company develops and manufactures peptides, as well as biocatalysts for use in the pharmaceutical and chemical industries. Further, it is developing biosimilar, inhalers, transdermal patches, vaccines, topicals, and depot injections. The company also exports its products. It serves multinational companies. The company has an agreement with COVAXX to develop and commercialize COVID-19 Vaccine for India and UNICEF. Aurobindo Pharma Limited was incorporated in 1986 and is headquartered in Hyderabad, India.